CARDIOMETABOLIC STRATEGIES IN HEART FAILURE AND CHRONIC KIDNEY DISEASE: FROM GLP-1 RECEPTOR AGONISTS TO IMPROVED QUALITY OF LIFE AND TECHNOLOGY-ENABLED CARE
DOI:
https://doi.org/10.31435/ijitss.1(49).2026.5402Keywords:
Heart Failure, Chronic Kidney Disease, Cardiovascular-Kidney-Metabolic Syndrome, GLP-1 Receptor Agonists, Semaglutide, Liraglutide, Tirzepatide, Hfpef, Digital Health, Wearable Devices, Precision MedicineAbstract
Heart failure (HF) and chronic kidney disease (CKD) frequently coexist and interact in a way that worsens prognosis, increases hospitalization risk, and reduces quality of life. This overlap is increasingly understood within the cardiovascular-kidney-metabolic (CKM) framework, which recognizes obesity, insulin resistance, type 2 diabetes, kidney dysfunction, and cardiovascular disease as interconnected components of a shared pathophysiological continuum rather than isolated disorders. In this context, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have attracted growing clinical interest because their actions extend beyond glycemic control and include body weight reduction, metabolic improvement, and favorable effects on selected cardiovascular and renal outcomes. The aim of this narrative review is to summarize the current evidence on GLP-1-based therapies in patients with HF and CKD, with particular emphasis on semaglutide, liraglutide, and tirzepatide. The review focuses on biological rationale, major clinical trials, practical implications, and the emerging role of precision phenotyping, digital health, wearable monitoring, and artificial intelligence in long-term CKM care. The structure of the review was informed by general scoping review principles, although it was not designed as a formal systematic review or meta-analysis. Available evidence suggests that GLP-1-based therapies may offer clinically meaningful benefits, particularly in patients with obesity, type 2 diabetes, HF with preserved ejection fraction (HFpEF), and CKD. Semaglutide has shown the strongest and most consistent evidence, improving symptoms, physical limitations, exercise capacity, and body weight in obesity-related HFpEF, while also reducing clinically important kidney outcomes in patients with CKD and type 2 diabetes. Liraglutide remains historically important because it helped establish cardiovascular benefit for the GLP-1 RA class, whereas tirzepatide represents a promising next-generation option in patients with a marked metabolic phenotype and obesity-related HFpEF. In conclusion, GLP-1-based therapies are becoming an important component of modern CKM care. Their relevance extends beyond glucose lowering and includes symptom improvement, better physical functioning, cardiovascular risk reduction, and kidney protection in selected populations. Future progress in this field will likely depend on more precise patient selection, better integration with existing cardiorenal therapies, and wider use of digital and phenotype-guided approaches to support individualized long-term care.
References
Abedi, A., Verma, A., Jain, D., Kaetheeswaran, J., Chui, C., Lankarany, M., & Khan, S. S. (2025). AI-driven real-time monitoring of cardiovascular conditions with wearable devices: Scoping review. JMIR mHealth and uHealth, 13, e73846. https://doi.org/10.2196/73846
Harrington, J., Gale, S. E., & Vest, A. R. (2024). Anti-obesity medications in patients with heart failure: Current evidence and practical guidance. Circulation: Heart Failure, 17(9), e011518. https://doi.org/10.1161/CIRCHEARTFAILURE.124.011518
Jamieson, A., Chico, T. J. A., Jones, S., Chaturvedi, N., Hughes, A. D., & Orini, M. (2025). A guide to consumer-grade wearables in cardiovascular clinical care and population health for non-experts. NPJ Cardiovascular Health, 2(1), 44. https://doi.org/10.1038/s44325-025-00082-6
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., Shah, S. J., Treppendahl, M. B., Verma, S., Abhayaratna, W., Ahmed, F. Z., Chopra, V., Ezekowitz, J., Fu, M., Ito, H., ... Petrie, M. C. (2023). Semaglutide in patients with heart failure with preserved ejection fraction and obesity. The New England Journal of Medicine, 389(12), 1069–1084. https://doi.org/10.1056/NEJMoa2306963
Kosiborod, M. N., Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M., Heerspink, H. J. L., Howlett, J., Kitzman, D. W., Verma, S., Chopra, V. K., Fu, M., Gustafsson, F., Jonk, A. M., Kumar, S., Lelonek, M., Lindegaard, M. L., Lopez-Sendon, J., Madan, K., Martinez, F. A., ... Shah, S. J. (2024). Semaglutide in patients with obesity-related heart failure and type 2 diabetes. The New England Journal of Medicine, 390(15), 1394–1407. https://doi.org/10.1056/NEJMoa2313917
Li, R., Liu, X., Chen, Y., Wang, J., Zhang, Y., Xu, L., Zhao, Q., Li, S., & Zhang, J. (2025). Machine learning-based phenotyping and assessment of treatment responses in heart failure with preserved ejection fraction. eClinicalMedicine, 79, 103462. https://doi.org/10.1016/j.eclinm.2025.103462
Liang, F., Gong, M., Zhang, M., Wang, Z., Wang, X., Li, J., Yu, Y., Lu, Y., Gu, D., Patel, A., Neal, B., & Lv, J. (2024). Applications of digital health approaches for cardiometabolic diseases prevention and management in the Western Pacific region. The Lancet Regional Health – Western Pacific, 43, 100817. https://doi.org/10.1016/j.lanwpc.2023.100817
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Marso, S. P., Plutzky, J., Ryan, D. H., Verma, S., & Wilding, J. P. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. The New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., Steinberg, W. M., Stockner, M., Zinman, B., Bergenstal, R. M., Buse, J. B., & LEADER Steering Committee and LEADER Trial Investigators. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. The New England Journal of Medicine, 375(4), 311–322. https://doi.org/10.1056/NEJMoa1603827
Nazir, A., Nazir, A., Jamal, M. S. W., Sadiq, S. U. R., Aman, S., Mustapha, M. J., Lawal, S. O., AbdulKareem, M. O., & Bamigbola, M. F. (2025). Wearable technology and its potential role in cardiovascular health monitoring and disease management. Health Science Reports, 8(11), e71486. https://doi.org/10.1002/hsr2.71486
Ndumele, C. E., Rangaswami, J., Chow, S. L., Neeland, I. J., Tuttle, K. R., Khan, S. S., Gulati, M., Johnson, A. E., Chandra, A., Ali, M. K., Ayala, C., Ballew, S. H., Blaha, M. J., Carnethon, M. R., Chou, E. L., Das, S. R., de Ferranti, S. D., Gidding, S. S., Hall, M. E., ... American Heart Association. (2023a). Cardiovascular-kidney-metabolic health: A presidential advisory from the American Heart Association. Circulation, 148(20), 1606–1635. https://doi.org/10.1161/CIR.0000000000001184
Ndumele, C. E., Neeland, I. J., Tuttle, K. R., Chow, S. L., Mathew, R. O., Khan, S. S., Ali, M. K., Ayala, C., Ballew, S. H., Blaha, M. J., Carnethon, M. R., Chou, E. L., DeBoer, M. D., de Ferranti, S. D., Hamburg, N. M., Kline-Rogers, E. M., Magge, S. N., Michos, E. D., Satterfield, B. A., ... American Heart Association. (2023b). A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: A scientific statement from the American Heart Association. Circulation, 148(20), 1636–1664. https://doi.org/10.1161/CIR.0000000000001186
Packer, M., Zile, M. R., Kramer, C. M., Kitzman, D. W., Cunningham, J. W., Verma, S., DeMets, D. L., Mathiasen, A. B., Holst, A. G., Butt, J. H., Shah, S. J., & SUMMIT Trial Study Group. (2025). Tirzepatide for heart failure with preserved ejection fraction and obesity. The New England Journal of Medicine, 392(5), 427–437. https://doi.org/10.1056/NEJMoa2410027
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., Pratley, R., & FLOW Trial Committees and Investigators. (2024). Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. The New England Journal of Medicine, 391(2), 109–121. https://doi.org/10.1056/NEJMoa2403347
Qi, Y., Mohamad, E., Azlan, A. A., Zhang, C., Ma, Y., & Wu, A. (2025). Digital health solutions for cardiovascular disease prevention: Systematic review. Journal of Medical Internet Research, 27, e64981. https://doi.org/10.2196/64981
Rasalam, R., Sindone, A., Deed, G., Audehm, R. G., & Atherton, J. J. (2025). State of precision medicine for heart failure with preserved ejection fraction in a new therapeutic age. ESC Heart Failure, 12(3), 1544–1557. https://doi.org/10.1002/ehf2.15205
Rosano, G. M. C., Vitale, C., & Spoletini, I. (2024). Precision cardiology: Phenotype-targeted therapies for HFmrEF and HFpEF. International Journal of Heart Failure, 6(2), 47–55. https://doi.org/10.36628/ijhf.2023.0058
Sebastian, S. A., Padda, I., & Johal, G. (2024). Cardiovascular-kidney-metabolic (CKM) syndrome: A state-of-the-art review. Current Problems in Cardiology, 49(2), 102344. https://doi.org/10.1016/j.cpcardiol.2023.102344
Tricco, A. C., Lillie, E., Zarin, W., O’Brien, K. K., Colquhoun, H., Levac, D., Moher, D., Peters, M. D. J., Horsley, T., Weeks, L., Hempel, S., Akl, E. A., Chang, C., McGowan, J., Stewart, L., Hartling, L., Aldcroft, A., Wilson, M. G., Garritty, C., ... Straus, S. E. (2018). PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. Annals of Internal Medicine, 169(7), 467–473. https://doi.org/10.7326/M18-0850
Xie, H., Yang, L., Jiang, B., Huang, Z., & Lin, Y. (2025). State-of-the-art wearable sensors for cardiovascular health: A review. NPJ Cardiovascular Health, 2(1), 53. https://doi.org/10.1038/s44325-025-00090-6
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Daria Sztefka, Agata Jaunich, Katarzyna Szlachetka, Adam Zając
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
